top of page

SITC 2024: With a TIL therapy having made it to the market for the first time this year, the CEO of KSQ Therapeutics describes what the next generation of TILs might look like

Qasim Rizvi says he believes TILs can have broad applicability in the solid tumor space. He describes how KSQ is knocking out SOCS1 and REGNASE-1 to solve the problem of T-cell exhaustion. The company's first two programs are now in the clinic.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

SAV_Logo_2024.png

At Savills, the Life Sciences Team specializes in helping biotech companies unlock their full potential by aligning real estate strategies with their scientific and business goals. As a leading global commercial real estate advisory firm, we focus exclusively on occupier services and tenant representation, acting as a trusted partner to some of the most innovative companies in the industry.

bottom of page